Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03563157 · ClinicalTrials.gov registry record · Phase 1
QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine
A Phase 1 study, sponsored by ImmunityBio.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT03563157 is a Phase 1 study that was terminated before completion, run by ImmunityBio. The registered enrollment target is 2 participants.
The verdict
NCT03563157, a Phase 1 study, was terminated before completion, sponsored by ImmunityBio.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
QUILT 3.071 NANT Colorectal Cancer (CRC) Vaccine: This is a Phase 1b/2 study investigating the effect of NANT CRC vaccine vs regorafenib in subjects with CRC who were previously treated with SOC.
Interventions
- BIOLOGICAL ALT-803
- BIOLOGICAL ETBX-011
- BIOLOGICAL ETBX-021
- BIOLOGICAL ETBX-051
- BIOLOGICAL Aldoxorubicin Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2018-09-28 |
| Est. Completion | 2019-08-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03563157
The ClinicalTrials.gov registry entry for NCT03563157 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ImmunityBio, which has 46 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which ALT-803 is the first listed.
NCT03563157 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03563157 about?
NCT03563157 is a clinical study titled "QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine". QUILT 3.071 NANT Colorectal Cancer (CRC) Vaccine: This is a Phase 1b/2 study investigating the effect of NANT CRC vaccine vs regorafenib in subjects with CRC who were previously treated with SOC.
What is the current status of trial NCT03563157?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2018-09-28. Estimated completion is 2019-08-21.
What interventions are being tested in trial NCT03563157?
The interventions under investigation include: ALT-803 (BIOLOGICAL), ETBX-011 (BIOLOGICAL), ETBX-021 (BIOLOGICAL), ETBX-051 (BIOLOGICAL), Aldoxorubicin Hydrochloride (BIOLOGICAL).
Who is sponsoring clinical trial NCT03563157?
This trial is sponsored by ImmunityBio, which has 46 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.